- Home
- NFBK vs ARVN Comparison
NFBK vs ARVN Comparison
Compare NFBK & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- ARVN
- Stock Information
- Founded
- NFBK 1887
- ARVN 2015
- Country
- NFBK United States
- ARVN United States
- Employees
- NFBK N/A
- ARVN N/A
- Industry
- NFBK Major Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- NFBK Finance
- ARVN Health Care
- Exchange
- NFBK Nasdaq
- ARVN Nasdaq
- Market Cap
- NFBK 482.5M
- ARVN 456.2M
- IPO Year
- NFBK 2007
- ARVN 2018
- Fundamental
- Price
- NFBK $10.88
- ARVN $7.84
- Analyst Decision
- NFBK Buy
- ARVN Buy
- Analyst Count
- NFBK 2
- ARVN 21
- Target Price
- NFBK $13.00
- ARVN $20.53
- AVG Volume (30 Days)
- NFBK 174.5K
- ARVN 1.9M
- Earning Date
- NFBK 07-23-2025
- ARVN 08-05-2025
- Dividend Yield
- NFBK 4.78%
- ARVN N/A
- EPS Growth
- NFBK 28.89
- ARVN N/A
- EPS
- NFBK 0.86
- ARVN N/A
- Revenue
- NFBK $133,079,000.00
- ARVN $426,900,000.00
- Revenue This Year
- NFBK $8.33
- ARVN $7.57
- Revenue Next Year
- NFBK $15.77
- ARVN N/A
- P/E Ratio
- NFBK $12.62
- ARVN N/A
- Revenue Growth
- NFBK 4.86
- ARVN 498.74
- 52 Week Low
- NFBK $9.40
- ARVN $5.90
- 52 Week High
- NFBK $14.39
- ARVN $30.24
- Technical
- Relative Strength Index (RSI)
- NFBK 33.02
- ARVN 53.58
- Support Level
- NFBK $11.18
- ARVN $7.32
- Resistance Level
- NFBK $11.57
- ARVN $8.05
- Average True Range (ATR)
- NFBK 0.27
- ARVN 0.42
- MACD
- NFBK -0.08
- ARVN -0.00
- Stochastic Oscillator
- NFBK 2.94
- ARVN 52.53
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.